Lyra Therapeutics (LYRA) Income from Continuing Operations (2019 - 2025)
Quarterly Income from Continuing Operations rose 36.69% to 6951000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 28919000.0 through Dec 2025, up 69.05% year-over-year, with the annual reading at 28919000.0 for FY2025, 69.05% up from the prior year.
Lyra Therapeutics' Income from Continuing Operations history spans 7 years, with the latest figure at 6951000.0 for Q4 2025.
- Income from Continuing Operations came in at 6951000.0 for Q4 2025, down from 5984000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5984000.0 in Q3 2025 to a low of 48131000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 12764000.0 (2021), against an average of 14190600.0.
- Year-over-year, Income from Continuing Operations crashed 208.18% in 2024 and then skyrocketed 84.55% in 2025.
- Lyra Therapeutics' Income from Continuing Operations stood at 13617000.0 in 2021, then fell by 4.44% to 14222000.0 in 2022, then decreased by 6.57% to 15156000.0 in 2023, then rose by 27.56% to 10979000.0 in 2024, then surged by 36.69% to 6951000.0 in 2025.
- Per Business Quant, the three most recent readings for LYRA's Income from Continuing Operations are 6951000.0 (Q4 2025), 5984000.0 (Q3 2025), and 7437000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | -8.50 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 727.20 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | -3.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Lyra Therapeutics | - | - | - | -6.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.95 Mn |
| Sep 30, 2025 | -5.98 Mn |
| Jun 30, 2025 | -7.44 Mn |
| Mar 31, 2025 | -8.55 Mn |
| Dec 31, 2024 | -10.98 Mn |
| Sep 30, 2024 | -11.87 Mn |
| Jun 30, 2024 | -48.13 Mn |
| Mar 31, 2024 | -22.45 Mn |
| Dec 31, 2023 | -15.16 Mn |
| Sep 30, 2023 | -15.65 Mn |
| Jun 30, 2023 | -15.62 Mn |
| Mar 31, 2023 | -16.26 Mn |
| Dec 31, 2022 | -14.22 Mn |
| Sep 30, 2022 | -14.77 Mn |
| Jun 30, 2022 | -14.37 Mn |
| Mar 31, 2022 | -11.91 Mn |
| Dec 31, 2021 | -13.62 Mn |
| Sep 30, 2021 | -11.06 Mn |
| Jun 30, 2021 | -11.04 Mn |
| Mar 31, 2021 | -7.80 Mn |
| Dec 31, 2020 | -7.02 Mn |
| Sep 30, 2020 | -6.33 Mn |
| Jun 30, 2020 | -4.54 Mn |
| Mar 31, 2020 | -4.23 Mn |
| Dec 31, 2019 | -4.35 Mn |
| Sep 30, 2019 | -4.16 Mn |
| Jun 30, 2019 | -4.20 Mn |
| Mar 31, 2019 | -3.59 Mn |